MAX

Overview

MAX is the obligate dimerization partner of MYC and a member of the MYC/MAX/MXD transcription factor network; loss-of-function alterations are recurrent in pheochromocytoma, neuroendocrine tumors, and a subset of GIST.

Alterations observed in the corpus

  • High-risk small bowel GIST class in the MSK elastic-net Cox genomic risk model was defined by alterations in any of MAX/MGA/MYC, CDKN2A, or RB1 (n=80 primary localized small bowel GIST) PMID:37477937.
  • 3 coding mutations with LOH identified in multiple myeloma (MM) whole-exome sequencing; MAX is the MYC heterodimerization partner and its dysregulation implicates MYC-axis disruption in MM pathogenesis PMID:24434212
  • Alteration identified as part of the actionable alteration list in cisplatin-resistant germ cell tumors (GCT) PMID:27646943
  • Germline MAX mutations observed as rare events in pheochromocytoma/paraganglioma, occurring specifically in the cortical admixture subtype (p<0.032) PMID:28162975

Cancer types (linked)

Co-occurrence and mutual exclusivity

  • Not specifically reported in the corpus.

Therapeutic relevance

  • Not directly therapeutically targeted in the corpus.

Open questions

  • None flagged.

Sources

This page was processed by entity-page-writer on 2026-05-15. - PMID:24434212

This page was processed by entity-page-writer on 2026-05-15. - PMID:27646943

This page was processed by entity-page-writer on 2026-05-15. - PMID:28162975

This page was processed by entity-page-writer on 2026-05-15.